SOPHiA GENETICS (SOPH) Q1 2026 earnings review
Strong Clinical Execution Drives Growth, Path to Profitability Narrows
SOPHiA GENETICS delivered a robust Q1 2026, with revenue accelerating 22% YoY to $21.7M, fueled by a record 107,576 platform analyses (+16% YoY). The company’s land-and-expand strategy is working flawlessly, evidenced by Net Dollar Retention surging to 117% (up from 103% a year ago). Higher-value applications like MSK-ACCESS and increasing U.S. market penetration are clearly driving the top line. However, the path to profitability remains a tightrope walk. While Adjusted EBITDA loss narrowed slightly by 3% to $9.2M, IFRS Net Loss actually widened 11% YoY to $19.3M, pressured by $1.7M in interest expenses and $0.7M in Guardant Health litigation costs. Management reaffirmed their target to approach Adjusted EBITDA breakeven by the end of 2026, supported by FY26 guidance of 20-22% revenue growth.
🐂 Bull Case
NDR jumped to 117% from 103% YoY, driven by incredibly low churn (0.2% annualized) and aggressive cross-selling of higher ASP products like the MSK-ACCESS liquid biopsy panel.
U.S. analysis volume grew 28% YoY, bolstered by major new partnerships with institutions like Mount Sinai, confirming the platform's scalability in the world's largest healthcare market.
🐻 Bear Case
Patent infringement lawsuits from Guardant Health remain an ongoing distraction and financial drain, adding $0.7M in net legal costs this quarter despite some early favorable interim cost awards.
The company used $15.1M in operating cash flow in Q1, leaving the cash balance at $65.4M. They rely heavily on their ATM facility ($14.5M raised in Q1) and debt to fund operations until breakeven.
⚖️ Verdict: ⚪
Neutral to Bullish. The core clinical business is firing on all cylinders with accelerating growth and excellent retention. If management can control external costs (litigation, FX) and maintain the current margin profile, the 2026 breakeven target is viable.
Key Themes
High-Value Applications Driving Product Mix
The strategic push into liquid biopsy and solid tumor profiling is paying off. The MSK-ACCESS and MSK-IMPACT applications have now crossed 100 signed customers globally. Q1 saw nearly 3,000 liquid biopsy analyses (up >100% YoY). This mix shift to more complex, higher-ASP panels is accelerating revenue growth faster than raw analysis volume growth (22% vs 16%).
Net Dollar Retention Surge
Accelerating. Net Dollar Retention (NDR) increased dramatically to 117% from 103% a year ago. This reflects highly successful same-store expansion and cross-selling motions. Management noted that existing accounts are adopting more applications, lowering customer acquisition costs and stabilizing the recurring revenue base. Annualized churn dropped to an exceptionally low 0.2%.
Guardant Health Litigation Costs
The ongoing patent infringement lawsuit from Guardant Health regarding the MSK-Access test continues to be a thorn in the company's side. While SOPHiA secured a €0.4M interim cost award in Q1, total net litigation expenses still hit $0.7M. If Guardant secures injunctive relief in the UK or EU, it could block significant regional revenue streams.
Cash Burn and Debt Service
Stable but concerning. Operating cash burn in Q1 was $15.1M (worse than the $10.7M burned in 25Q1). Total cash stands at $65.4M. To preserve liquidity, the company utilized its ATM program heavily, selling 2.86M shares for $14.5M. Additionally, interest expense surged 153% YoY to $1.7M due to the $35M Tranche B drawdown in mid-2025. This debt burden offsets some of the operational leverage gained from higher gross margins.
BioPharma Segment Reactivation
Management noted that the BioPharma business is finally delivering positive growth and is modestly accretive to the overall growth rate. While they warned that pharma is a "long cycle business" avoiding hockey-stick projections, the launch of real-world evidence initiatives with AstraZeneca and a new Top 5 pharma partner confirms the segment is transitioning from a headwind to a tailwind.
Other KPIs
Accelerating. Up 21% YoY, representing 97% of total revenue. This is driven by 16% volume growth and positive pricing/mix effects from oncology applications like HemOnc and Hereditary Cancer.
Stable. Down slightly from 75.7% in 25Q1, but still demonstrating massive operating leverage. The company's cloud-native architecture allows them to process substantially higher data volumes without a linear increase in computing costs.
Accelerating. Up from 490 in 25Q1. The company added 18 new core customers in Q1 alone, including prestigious institutions in France, the Netherlands, and India, validating their global land-and-expand approach.
Guidance
Accelerating. The midpoint of $93M implies a ~20.3% YoY growth rate compared to FY25's $77.27M. This assumes a back-half weighted ramp as massive health system contracts signed in 2025 transition out of the implementation backlog and into routine clinical use.
Reversing. Implies a significant improvement from the $41.5M loss in FY25. Achieving the $30.5M midpoint will rely on maintaining ~75% adjusted gross margins while holding operating expenses relatively flat in local currencies.
Key Questions
Guardant Health Litigation Contingencies
With the UK and EU lawsuits ongoing, what specific operational or financial contingencies are in place if an injunction restricts the sale of MSK-ACCESS in these high-growth regions?
Capital Adequacy & ATM Utilization
You raised $14.5M via the ATM in Q1. Given the $15.1M quarterly operating burn and the target of reaching EBITDA breakeven by late 2026, do you expect to fully exhaust the remaining $35.5M ATM authorization this year?
BioPharma Revenue Ramp
BioPharma is noted as being modestly accretive to growth now. What are the specific milestones required in the AstraZeneca and Top 5 Pharma contracts to trigger the larger, step-function revenue recognition events?
Implementation Backlog Conversion
You signed a record 124 customers in 2025. What is the current average time-to-revenue for a complex deployment like MSK-ACCESS, and how is the newly streamlined implementation team reducing this timeline?